O TYM ODCINKU
David Shulman, MD, joins us on OsteoBites to discuss the newly opened phase 1/2 study to evaluate LNTH-2403, a LRRC15-targeted radiopharmaceutical, in patients with relapsed/refractory osteosarcoma.
For many years, LRRC15 has been known to be an important target in osteosarcoma. A prior study showed a strong signal of activity of an LRRC15-targeted therapy in osteosarcoma; however, the development of the agent was not pursued. There is now a novel LRRC15-targeting radiopharmaceutical that has entered clinical trials for patients with osteosarcoma, and Dr. Shulman will provide an overview of this newly opened trial.
Dr. David Shulman is a Pediatric Oncologist and clinical/translational researcher at Dana-Farber Cancer Institute, where he also serves as an Assistant Professor of Pediatrics at Harvard Medical School. As the Director of the DFCI AYA Sarcoma Program, he focuses his clinical practice on the specialized care of adolescents and young adults (AYA) diagnosed with sarcomas. His research program, which has received support from the NIH and Harvard Catalyst, is dedicated to improving patient outcomes through the investigation of novel therapeutic approaches and the utility of circulating tumor DNA (ctDNA) as a clinical biomarker. He leads a national liquid biopsy study for patients with Ewing sarcoma and osteosarcoma, known as the LEOPARD study.
